Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Dr. Zhicheng Dong
ACROBiosystems Product Manager
Topic：
Addressing Challenges in Antibody-Drug Conjugate Development
Speaker Bio:
Clarence DEFFAUD est titulaire d'un doctorat en biologie moléculaire et cellulaire de l'Ecole Normale Supérieure de Lyon (ENS, INSERM U412 - LaboRetro). Après sa thèse, il a fondé IRESYS, une start-up spécialisée dans la découverte de médicaments basée sur le criblage combinatoire de banques de cellules et a déposé un brevet (PCT / FR2002 / 004124). En 2003, il rejoint HYBRIGENICS, une société spécialisée dans les interactions protéine-protéine, en tant que « Yeast two Hybrid Service Manager » et participe à la réalisation de divers projets scientifiques, dont la création de nouvelles banques d'expression. Il a également co-fondé BIO-RD. Clarence DEFFAUD a rejoint BIOTEM en 2005 en tant que CEO/CSO. Depuis 2005, il a supervisé plus de 1000 projets, dont le développement d'anticorps monoclonaux pour la recherche, le diagnostic et la thérapeutique.
Antibody-drug conjugates (ADCs) represent a groundbreaking approach to cancer treatment. They involve combining monoclonal antibodies with chemotherapy drugs, enabling the precise targeting of cancer cells while minimizing damage to healthy tissues. Despite their considerable potential, the development of ADCs poses challenges such as conjugation efficiency, drug release at the target site, and side effect management.
This report will explore the recent advancements in ADC technology, delve into the components that influence ADC functionality, and propose strategies to address the pivotal challenges encountered during the development phase, including optimizing the antibody, improving payload conjugation and evaluating payload delivery.
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.
This web search service is supported by Google Inc.
A-Z
